Rani Therapeutics (RANI) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Rani Therapeutics (RANI) over the past year, losing 28.3% versus a loss of 68.6%. Over five years, XLO leads with a -97.3% price change compared with -98.3% for RANI. Rani Therapeutics is the larger company by market cap ($59.0 million vs $53.4 million), about 1.1 times the size, while Xilio Therapeutics is growing revenue faster (+589.9% vs +58.9%).
Xilio Therapeutics converts more of its revenue into profit, with a net margin of -80.1% versus -1817.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | XLO |
|---|---|---|
| Share price | $0.5111 | $7.56 |
| Market cap | $59.03M | $53.40M |
| 1-day change | -11.97% | -1.11% |
| YTD return | -62.14% | -15.63% |
| 1-year return | -68.64% | -28.29% |
| 5-year return | -98.34% | -97.29% |
| P/E ratio (TTM) | — | 11.63 |
| EPS (TTM) | $-0.06 | $0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.63M | $43.77M |
| Revenue growth (YoY) | +58.85% | +589.88% |
| Net income (latest FY) | $-29.67M | $-35.04M |
| Operating margin | -2345.99% | -95.92% |
| Net margin | -1817.09% | -80.05% |
| 52-week high | $1.69 | $10.71 |
| 52-week low | $0.502 | $6.47 |
| Distance from 52-week high | -69.76% | -29.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1308.73% | +164.55% |
| Average volume | 545.67K | 11.54K |
| Shares outstanding | 115.49M | 7.06M |
| Employees | 69 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed RANI by 40.4 percentage points over the past year.
- Xilio Therapeutics is more profitable, keeping -80.1 cents of every revenue dollar as net income versus -1817.1 cents for Rani Therapeutics.
- Xilio Therapeutics grew revenue faster in its latest fiscal year (+589.88% vs +58.85%).
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
RANI vs XLO FAQ
Which is bigger, Rani Therapeutics or Xilio Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $53.40M for Xilio Therapeutics (XLO).
Which stock has performed better over the past year, RANI or XLO?
XLO returned -28.29% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Rani Therapeutics and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.